Because of the recent lack of availability of streptomycin-currently considered the drug of choice for the treatment of tularemia-we reviewed the literature on alternative drugs that have been used for this purpose. In addition, we reviewed data on the in vitro susceptibility of Francisella tularensis to a wide variety of agents. The rate of cure for streptomycin was 97%, with no relapses. For gentamicin and tetracycline, respectively, the rates of cure were 86% and 88%, the rates of relapse were 6% and 12%, and the rates of failure were 8% and O. The duration of therapy with gentamicin and a delay in its initiation may have affected outcome in severe cases. For chloramphenicol and tobramycin, cure rates were 77% and 50%, respectively; relapse rates were 21% and 0; and failure rates were 2% and 33%, respectively. Treatment with imipenemjcilastatin was successful in one case, and that with ciprofloxacin or norfloxacin was successful in six cases; in contrast, therapy with ceftriaxone was ineffective in eight cases. On the basis of this review, we conclude that gentamicin is an acceptable alternative to streptomycin for the treatment of tularemia.
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Tularemia, a gram-negative infection caused by Francisella tularensis. was first described in 1925 . The clinical manifestations of this infection can be glandular, ulceroglandular, oculoglandular, oropharyngeal, typhoidal, and pneumonic [I] . Several clinical reviews of tularemia have been published [1] [2] [3] [4] [5] . This article reviews the use of streptomycin and alternative agents in the treatment oftularemia.
Streptomycin has long been considered the drug of choice for tularemia. Commercial supplies of streptomycin were recently unavailable, but the drug can now be obtained from Pfizer (New York) on an individual-case basis [6] .
No prospective, controlled clinical trials have evaluated the efficacy of antimicrobial agents, including streptomycin, in the treatment of tularemia. However, the literature is replete with case reports. Herein we review the published experience to date with antimicrobial treatment of tularemia, we detail cases in which therapy failed, and we discuss the in vitro activity ofantimicrobial agents other than streptomycin against F. tularensis.
Materials and Methods
Computerized MEDLINE and International Pharmaceutical Abstracts were searched for English-language reports published before April 1993. Additional reports were identified in the bibliographies of these articles. We did not in-elude studies of animals or experimentally induced tularemia. Since most of the articles identified dealt with small populations of patients with tularemia and since many were case reports, a statistical analysis was not conducted.
Results

Outcome of Antimicrobial Therapy
Streptomycin. Our review identified 224 patients who received streptomycin as the primary therapeutic agent [I, 4, 7-12] (table I) . Of these 224 patients, 217 were treated successfully, one became more ill, and six died. No instances of relapse were noted. Some patients received other antibiotics either before or concurrently with streptomycin, but in no case were these other agents considered effective against tularemia. Evans et al. described one patient whose infection worsened despite treatment with streptomycin and one patient who died after experiencing a Jarisch-Herxheimer-like reaction to streptomycin [4] . The latter reaction is attributed to excess antigen resulting from the drug's "bactericidal efficiency" and leading to exacerbation of signs and symptoms. Continuation oftherapy usually results in the patient's recovery [13] . No instances of this reaction to other drugs were documented.
Giddens et al. reported the use of streptomycin in 141 cases of tularemia [7] . Most patients received 1-3 g ofstreptomycin or dihydrostreptomycin daily. The duration offever was the best indicator of response; the patient's temperature usually fell within 3 days, but duration ranged from I day to 40 days. The authors concluded that doses of streptomycin of > 2 g provided no additional benefit. In this series, five patients treated with streptomycin died (mortality, 3%), as did six patients treated with other antibiotics. Renal dysfunction was the most serious complication, occurring in six of these II patients. Typhoidal tularemia was the most frequent fatal form of infection. The authors reported a mortality of 33% among 169 patients treated before streptomycin became available [7] .
Gentamicin. Twenty-one articles described 36 patients who received gentamicin [4, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] (table I) . Of these patients, 31 had their infections cured, 2 experienced a relapse, 2 became more ill, and I died. Of the 31 successfully treated patients, 13 received gentamicin only, 10 received gentamicin along with other antibiotics not effective against tularemia, 4 received gentamicin after the failure of therapy with a tetracycline or chloramphenicol, 3 received gentamicin concomitantly with chloramphenicol or a tetracycline, and I received gentamicin but also received tetracycline on discharge, despite the resolution of disease. Of the articles reviewed, that by Mason et al. reported the largest-scale experience with gentamicin treatment-i.e., a study of 9 patients [I4].
Gallivan et al. reported a case of ulceroglandular tularemia that resulted in the death ofa 65-year-old man [15] . The patient presented with a 5-day history of spiking fever, shaking chills, and a nonhealing ulcer on his left hand. After 10 days of hospitalization, he reported abdominal pain and underwent exploratory laparotomy; he developed progressive bilateral pneumonitis postoperatively. Treatment with cephalothin and gentamicin was started 15 days after the onset of symptoms. Therapy with doxycycline and streptomycin was begun after documentation of the presence of antibody to F. tularensis. Pneumonitis worsened: disseminated intravascular coagulation and renal failure developed. The patient died 28 days into the course of the disease. Evans et al. described two patients, one of whom had chronic lymphocytic leukemia and was admitted with a rectal temperature of J05°F, diffuse pneumonia, and septic shock [4] . Blood cultures were positive for F. tularensis. and treatment with gentamicin was initiated. Because of a dramatic response, gentamicin therapy was stopped after 6 days. but relapse occurred 17 days later. The second patient had been gravely ill, with fever. confusion. pneumonia. and hepatitis. This patient did not respond to 4 days of treatment with gentamicin and responded only slowly after the regimen was changed to streptomycin.
Lovell et al. reported a case of glandular tularemia in a 13-month-old child: in this case the diagnosis and the initiation of appropriate therapy were delayed for 43 days [17] . The patient responded to 9 days of treatment with gentamicin and ampicillin. However. 5 days after discharge. he experienced a relapse. with tularemic meningitis. The infecting organism was not identified until the patient's second admission, when CSF cultures yielded F. tularcnsis. The patient was successfully treated with a 2-week course of chloramphenicol.
Roy et al. reported on a 42-year-old man admitted to the hospital with a 7-day history offever. anorexia. malaise. nonproductive cough. and diarrhea [18] . The patient was treated with erythromycin and gentamicin for coverage of tularemic pneumonia and legionella infection. His respiratory status deteriorated, and the administration of gentamicin was discontinued after 24 hours. Therapy with rifarnpin was initiated for increased coverage of legionella pneumonia. Tularemia was later diagnosed on the basis of positive cultures. and the patient made slow but steady progress. He was discharged during a course of treatment with doxycycline.
Chloramphenicol. I) . Of these patients, 33 had their infections cured. one became more ill, and nine experienced a relapse. Of the 33 patients whose therapy was successful. 31 received only chloramphenicol and two received both chloramphenicol and gentamicin. The one patient whose condition worsened and the nine patients who had relapses received chloramphenicol only.
Dienst reported cures of tularemia in 16 patients treated with chloramphenicol, although the condition ofone patient at Penn State University (Paterno Lib) on February 21, 2016 http://cid.oxfordjournals.org/ Downloaded from later worsened and one patient's infection relapsed [13] . The latter patient responded to a continuation of chloramphenicol therapy. Evans et al. described three patients whose infections relapsed after the discontinuation of treatment with chloramphenicol; these infections were cured by streptomycin therapy [4] . Jacobs and Narain described four children treated with chloramphenicol [26] . One infection was cured, but three relapsed within 72 hours of the completion of a 7-to 10-day course of therapy.
Parker et al. described a 27-year-old man with pneumonic tularemia who was treated with chloramphenicol beginning on day 6 of disease [35] . An initial oral dose of 3 g was followed by doses of I g every 8 hours. The patient was afebrile and asymptomatic after 36 hours, and therapy was discontinued after 5 days. On the 17th day, a relapse resulted in the start of a second course of treatment with chloramphenicol (total. 109); the patient became asymptomatic after 12 hours. Two days after the discontinuation of this second course, recrudescence was again documented. A third course of chloramphenicol (18 g over 7 days) was curative. In another case, a 35-year-old patient with ulceroglandular tularemia presented with fever, chills, and headache. An initial dose of 3.5 g of chloramphenicol was followed by doses of 0.5 g every 4 hours for 5 days; the patient defervesced. Three days later, fever and symptoms returned. Therapy with chloramphenicol was reinstituted for 4 more days, and the patient's condition improved.
Tobranivcin. Four articles described six cases of tularemia in which tobramycin was used [20, 27, 30, 34] (table I) . Three patients recovered and two patients died; the outcome of the remaining case was not stated. All six patients were severely ill. with complications including sepsis, diabetes, rhabdomyolysis, and renal failure. The total duration of tobramycin therapy was not stated in four cases. Kaiser et al. described the death of a 63-year-old woman with a 7-day history of fever. chills, cough, malaise, mvalgias, lethargy, and confusion [27] . The patient had symptoms suggestive of typhoidal tularemia and developed renal failure secondary to rhabdomyolysis. She was initially treated with cefazolin and tobramycin and became afebrile within 24 hours. The therapeutic regimen was changed to chloramphenicol and cefotaxime because of the need for dialysis on day 6. The patient subsequently developed disseminated intravascular coagulation and died. Provenza et al. described the death of a 75-year-old woman who was septic upon presentation to the hospital after several weeks of symptoms [30] . The patient had renal insufficiency and hypertension. She was initially treated with vancomycin, tobramycin, and corticosteroids and died 2 days after admission.
Tetracvcline. A total of 13 articles described 50 patients treated with tetracycline [I, 4, 14, 16, 26, 28, 36-42] (table   I) . Forty-four patients had their infections cured, while six patients had a relapse. Of the 44 successfully treated patients, 31 received tetracycline alone, three received tetracycline and gentamicin, and 10 received tetracycline and other antibiotics not effective against tularemia. Of the six patients with relapses, two were treated with tetracycline and other antibiotics not effective against tularemia, three with tetracycline alone, and one with tetracycline and streptomycin. Caruso et al. reported on a 38-year-old woman who presented with a 9-day history of oropharyngeal tularemia, which was treated initially with ampicillin and then with erythromycin [21] . Approximately 22 days after the onset of symptoms, therapy with tetracycline (250 mg orally every 6 hours) and streptomycin (500 mg intramuscularly every 12 hours) was initiated. The duration of therapy was not stated. This patient was readmitted 2 months later with enlarged cervical nodes and was treated with chloramphenicol and gentamicin. The wounds stopped draining after 2 weeks and healed after 2 months; cultures were negative. Adenitis with late suppuration of regional lymph nodes has been reported in successfully treated cases, although drainage of these nodes reveals necrotic tissue that is sterile [8] .
Evans et al. reported three relapses of infections treated with tetracycline and described two of these instances [4] . One case involved a 13-year-old girl whose oropharyngeal tularemia was treated first with cefaclor and then with tetracycline. She continued to have low-grade fever and tender lymph nodes, and her regimen was changed to streptomycin. Her fever responded to this therapy, but her lymphadenopathy persisted. The other case involved a 72-year-old man with ulceroglandular tularemia who defervesced 24 hours after the start of tetracycl ine therapy. Administration of the drug was inadvertently discontinued, and fever returned. After tetracycline therapy was reinitiated, the patient defervesced and his pneumonia cleared. He later received a course of streptomycin, but further details were not given.
Penn and Kinasewitz described two patients whose infections relapsed despite tetracycline therapy [16] . Both patients received <7 days of therapy and had underlying medical conditions (e.g., diabetes) that may have contributed to the relapse.
Quina/ones. Syrjala et al. reported on three patients with pneumonic tularemia and one with ulceroglandular tularemia who were successfully treated with ciprofloxacin (750 mg twice a day) [43] . These authors also described one patient with ulceroglandular tularemia who responded to therapy with norfloxacin (400 mg twice a day for 10 days). Neither the severity of illness nor the presence or absence of underlying complications was discussed. All five patients responded to treatment within 48 hours, and no relapses occurred within 6 months.
Scheel et al. reported the case of a veterinary surgeon with ulceroglandular tularemia [44] . He treated himself intermittently with doxycycline and then with amoxicillin for 10 days, but his adenitis persisted. He switched back to doxycycline for 3 weeks, and his condition improved. However. 3 days after the completion of doxycycline therapy, the infection relapsed. After presenting for treatment, the patient re- [43] . They noted a narrower range among the MBCs of ciprofloxacin and norfloxacin for the various strains: this finding suggested that these agents may be preferable to others in this class.
Drug
On the basis of this review, we believe that gentamicin is comparable to streptomycin in efficacy against tularemia. Treatment with gentamicin failed in some instances, but several of the patients involved received <6 days of therapy. Additional factors contributing to failures in these patients included severe illness, the presence or underlying diseases. and a delay in the initiation of therapy. Data on serum concentrations of the drug were often unavailable. MIC 90 values for gentamicin and streptomycin against F. tularensis have Erythromycin Tetracycline Chloramphenicol T rimethoprirn-sul farnethoxazole Gentamicin Clindamycin ceived ciproftoxacin (750 mg twice daily) for 2 weeks. Axillary adenitis resolved. No signs of relapse were detected at a follow-up examination 2 months later.
lmipenemlcilastatin. Lee et a1. described a patient who had pneumonic tularemia with renal failure and chronic obstructive airway disease as well as alcohol-related cardiomyopathy [45] . Although seriously ill, the patient responded to therapy with imipenern/cilastatin (500 mg intravenously every 8 hours for 14 days). No relapse was evident at a l-year follow-up examination.
Antimicrobial Susceptibility of F. tularensis
In vitro studies have shown F. tularensis to be susceptible to a wide range of antimicrobial agents, many of which have not been studied for the treatment of patients with tularemia. We found five articles that reported the details of antimicrobial susceptibility testing: the methods used differed by investigator [14, 42, 43, 46, 47] . Such testing showed no difference between type A and type B strains of F. tularensis [47] . The results of tests with isolates from ticks and from humans are summarized in tables 2 and 3, respectively.
In light of the in vitro susceptibility data reported by Baker et a1. [46] and by Markowitz et al. [47] , it appears that the third-generation cephalosporins or amikacin would be effective against tularemia [46, 47] . However, Cross and Jacobs have compiled data showing that ceftriaxone is in fact ineffective for the treatment of tularemia [48] (table I) . In eight documented cases of tularemia, patients were initially been reported as 2 JIg/mL and 4 JIg/mL, respectively [43] . Peak concentrations of gentamicin at the higher end of the therapeutic range (i.e., 8-12 JIg/mL) would be desirable. The disadvantages of streptomycin include higher MICs, increased vestibular toxicity, and delays encountered in obtaining the drug [49, 50] . The observed susceptibility and clinical responses to gentamicin lead us to conclude that it should currently be considered the alternative drug of choice for serious cases of nonmeningitic tularemia. Our review revealed comparable cure rates for gentamicin and tetracycline-rates exceeding those for tobramycin and chloramphenicol. The initial response to therapy with tetracycline was comparable to the initial response to streptomycin or gentamicin. However, tetracycline was associated with twice as many relapses as gentamicin. Rates of relapse are higher when bacteriostatic agents are used in the treatment of tularemia [51] . Of the six patients whose infections relapsed despite therapy with tetracycline, two were treated for <7 days, while the duration of treatment was not stated in the other four cases. The availability of oral preparations of tetracycline is an advantage, but the levels attained do not exceed the MIC by a considerable amount and oral absorption is reduced by~50% by food, milk, and many antacids [52] .
In short, tetracycline appears to be a reasonable alternative to gentamicin, offering the option of oral treatment of less severely ill patients; however, caution is required because of the relatively high rate of relapse. A longer course of treatment may be advantageous in reducing the relapse rate. Because tetracycline may cause tooth discoloration in children <8 years old and bone deposition in the developing fetus, another agent would be preferable for the treatment of young children and pregnant women.
Among 43 patients receiving chloramphenicol, the cure rate was 77%-a figure significantly lower than that reported for streptomycin. The failure rate was only 2%, but the relapse rate was the highest reported-21 %. Like that for tetracycline, the relapse rate for chloramphenicol is higher than those for bactericidal drugs [26, 53] . This is surprising, as the available MIC 90 and MBC for two isolates were both I JIg/ mL and the peak therapeutic levels achievable with chloramphenicol are 20-25 JIg/mL [42, 46] . One advantage of chi oramphenicol over both aminoglycosides and tetracycline is good penetration of the CNS [52] . Concentrations of chloramphenicol in the CSF are 21 %-50% of concurrent concentrations in the plasma of patients with uninflamed meninges and 45%-89% of concurrent plasma levels in patients with inftamed meninges. Even with inftamed meninges, CSF concentrations of gentamicin are unpredictable, varying from 0 to 50% of concurrent serum concentrations [52] . Thus the use of chloramphenicol should be considered when tularemic meningitis is suspected. In one reported case, tularemic meningitis was successfully treated with 2 weeks of chloramphenicol after the failure of a 9-day course of gentamicin [17] .
Only six patients received tobrarnycin: information on dose, duration, and serum level was often lacking [46] . Tobramycin had the lowest cure rate (50%) and the highest failure rate (33%). Even though the MIC data for this drug are comparable to those for gentamicin, the rate of response was clearly much lower. The reasons for the failure of tobramycin therapy in these cases may not have been attributable to the drug itself. All six patients were severely ill, with major complications; moreover, the number of patients treated was too small for adequate conclusions on efficacy. Until more in vivo data are available, neither tobramycin nor amikacin can be considered for the treatment of tularemia.
In one case a l4-day course of therapy with imipenern/ cilastatin was successful in a patient seriously ill with pneumonic tularemia [45] . No MIC data are available on the susceptibility of F. tularensis to imipenem/cilastatin. Further studies are needed before this agent can be recommended.
Successful outcomes of treatment and favorable in vitro susceptibility data indicate that ciproftoxacin and norftoxacin are potential alternatives in treatment of tularemia. The narrower range of MBCs for these two agents than for other quinolones suggested that they would be more reliable. These results are promising, but further studies are needed [43] . Pneumonia frequently complicates tularemia, and its etiology may be uncertain; thus ciproftoxacin should be used with caution, since overwhelming pneumococcal sepsis and meningitis may result [54, 55] .
Data on antimicrobial susceptibility are favorable for new antibiotics such as ceftazidime. However, further clinical studies of the drug's efficacy are needed. The importance of this information is underscored by the inadequate clinical response of eight patients to ceftriaxone despite favorable MIC data.
In conducting this review, we found that many case reports lacked sufficient information on dose, type of tularemia, concomitant therapy, and/or serum drug levels. These deficiencies made the analysis of data difficult. Since the duration of therapy was not stated in most of the articles reviewed, the optimal duration could not be determined. However, many infections relapsed or worsened when the duration of therapy was <7 days. Patients who are severely ill or who are treated with bacteriostatic agents should receive longer courses of therapy. In the future, case reports should include information on all of the factors just mentioned so that presumed causes of failures of treatment can be accurately assessed.
